MedTrace Logo

A Study of STAR-0215 in Healthy Adult Participants

NCT05477160 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2024-01-11

No results posted yet for this study

Summary

This is a first-in-human, single-center, randomized, double-blind, placebo-controlled, single ascending dose study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single subcutaneous (SC) or intravenous (IV) administration of STAR-0215 in healthy adult participants.

Conditions

Interventions

DRUG

STAR-0215 (SC)

STAR-0215 will be administered as an SC bolus injection.

DRUG

Placebo (SC)

Placebo will be administered as an SC bolus injection.

DRUG

STAR-0215 (IV)

STAR-0215 will be administered as an IV bolus injection.

DRUG

Placebo (IV)

Placebo will be administered as an IV bolus injection.

Sponsors & Collaborators

  • Astria Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-27
Primary Completion
2023-11-17
Completion
2023-11-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05477160 on ClinicalTrials.gov